SUMMARY: The FDA has approved a new drug called Lecanemab for the treatment of Alzheimer's disease. It has been shown to slow the progression of the disease, providing hope for the six million Americans living with Alzheimer's, especially those over 65. The drug is administered through infusion every two weeks, and there are potential risks including brain swelling and bleeding. The drug is sold under the brand name Lequembi and has an annual cost of $26,000. Medicare may cover the cost, and doctors are optimistic about the potential benefits of the drug. The goal of finding a cure for Alzheimer's disease continues.

Read More

The post New Alzheimer's drug could have big impact on Mississippi appeared first on www.wjtv.com